5Clinical and Laboratory Standards Institute. M100-S22Performance standards for antimicrobial susceptibility testing standards:twenty-second informational supplement[S].Wayne PA:CLSI,2012. 被引量：1
6Demiraslan H,Sevim M,Pala C. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients[J].International Journal of Hematology,2013.414-420. 被引量：1
8Crossman LC,Gould VC,Dow JM. The complete genome,comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants[J].Genome Biology,2008.R74. 被引量：1
5Mendoza DL,Darin M,Waterer GW,et al.Update on stenotro-phomonas maltophilia infection in the ICU.Clinical Pulmonary Med,2007,14(1):17-22. 被引量：1
6Pathmanathan A,Waterer GW.Significance of positive stenotro-phomonas maltophilia culture in acute respiratory tract infection.Eur Respir J,2005,25:911-914. 被引量：1
7Di Bonaventura G,Pompilio A,Zappacosta R,et al.Role of excessive inflammatory response to stenotrophomonas maltophilia lung infection and in DBA/2 mice:implications for cystic fibrosis.Infect Immun,2010,78(6):2466-2467. 被引量：1
8Clinical and Laboratory Standards Institute(CLSI)/NCCLS. Performance Standards for Antimicrobial Susceptibility tes ting Standards twentyth Informational Supplement [S]. 2010, M100-s20. 被引量：1
10Yao JD, Louie M,Louie L, et al. Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas(Xanthomonas) maltophilia[J]. J Clin M icrobio, 1995, 33(5) .. 1428-1430. 被引量：1
2Di Bonaventura G,Spedicato I,D′Antonio D,et al.Biofilm formation by stenotrophomonas maltophilia:modulation by quinolones,trimethoprimsulfamethoxazole,andceftazidime.Antimicrob Agents Chemother 2004,48(1):151-160. 被引量：1
3Furushita M,Okamoto A,Maeda T,et al.Isolation of multidrug-resistant stenotrophomonas maltophilia from cultured yellowtail(seriola quinqueradiata)from a marine fish farm.Appl Environ Microbiol,2005,71(9):5598. 被引量：1
